

Evidence dossier - RTW Investments

GetCoattail manager profile: <https://getcoattail.com/manager/rtw-investments> | CIK 0001493215 | Rank #34 of 149 tracked managers by reported 13F value.

Background: Founded: 2009 | HQ: New York, New York, US | Style: Healthcare and biotech investing across the full life cycle | Key person: Roderick Wong

Background

source:

<https://www.businesswire.com/news/home/20220106005257/en/RTW-Investments-Bolsters-Leadership-Team-With-Key-Executive-Appointments>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-14 Reported total value: \$11.7B Positions: 84 Top-10 concentration: 47.7% of reported value.

Ticker	Company	Weight	Reported value
MDGL	Madrigal Pharmaceuticals Inc	9.14%	\$1.1B
ARGX	Argenx Se	5.62%	\$658M
PTCT	Ptc Therapeutics Inc	5.39%	\$632M
PTGX	Protagonist Therapeutics Inc	5.30%	\$620M
CGON	Cg Oncology Inc	5.16%	\$605M
INSM	Insmed Inc	4.41%	\$516M
TNGX	Tango Therapeutics Inc	3.71%	\$435M
SYRE	Spyre Therapeutics Inc	3.22%	\$377M
CELC	Celcuity Inc	2.95%	\$346M
ERAS	Erasca Inc	2.81%	\$329M

2. Hypothetical 13F-clone results

Window: 2016-11-18 to 2026-10-02 (40 filings). Cumulative: +61.9% CAGR: +5.00% SPY same window: cumulative +312.5%, CAGR +15.44%. Trailing CAGR - 10Y: n/a, 5Y: +0.06%, 3Y: +20.57%, 1Y: +26.22%. Max drawdown (month-end, approximate): -65.2%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001493152-16-015263	2016-11-18	34
2016Q4	0001493152-17-001592	2017-02-15	31
2017Q1	0001493152-17-005309	2017-05-15	28
2017Q2	0001493152-17-009184	2017-08-14	28
2017Q3	0001493152-17-012995	2017-11-14	27

2017Q4	0001493152-18-002731	2018-02-28	32
2018Q1	0001493152-18-006734	2018-05-14	38
2018Q2	0001493152-18-011640	2018-08-14	40
2018Q3	0001493152-18-015906	2018-11-14	46
2018Q4	0001493152-19-002190	2019-02-15	1
2019Q1	0001493152-19-007228	2019-05-15	50
2019Q2	0001493152-19-012319	2019-08-14	52
2019Q3	0001493152-19-017406	2019-11-14	60
2019Q4	0001493152-20-002551	2020-02-14	1
2020Q1	0001493152-20-009119	2020-05-15	65
2020Q2	0001493152-20-015797	2020-08-14	77
2020Q3	0001493152-20-021624	2020-11-16	90
2020Q4	0001493152-21-003922	2021-02-16	102
2021Q1	0001493152-21-011440	2021-05-14	111
2021Q2	0001493152-21-019742	2021-08-13	113
2021Q3	0001493152-21-028680	2021-11-15	120
2021Q4	0001493152-22-004326	2022-02-14	124
2022Q1	0001493152-22-013567	2022-05-16	106
2022Q2	0001493152-22-022708	2022-08-15	107
2022Q3	0001493152-22-032245	2022-11-14	86
2022Q4	0001493152-23-004608	2023-02-14	77
2023Q1	0001493152-23-016865	2023-05-15	60
2023Q2	0001493152-23-028029	2023-08-14	62
2023Q3	0001493152-23-040729	2023-11-14	67
2023Q4	0001493152-24-006286	2024-02-14	64
2024Q1	0001493152-24-019465	2024-05-15	69
2024Q2	0001493152-24-031911	2024-08-14	68
2024Q3	0001493152-24-045409	2024-11-14	68
2024Q4	0001493152-25-006608	2025-02-14	72
2025Q1	0001493215-25-000003	2025-05-15	68
2025Q2	0001493215-25-000007	2025-08-14	73
2025Q3	0001493215-25-000054	2025-11-14	74
2025Q4	0001493215-26-000060	2026-02-17	91
2026Q1	0001493215-26-000130	2026-05-15	88
2026Q2	0001493215-26-000164	2026-08-14	84

4. Coverage and adjustments

Price coverage at the latest filing: 82.3% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.